ArticleFrontiers in oncology2024

Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition.

Georgios Lyrarakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.